3B Blackbio

Why is 3B Blackbio DX Ltd falling/rising?

As of 13-Jul, the stock price of 3B Blackbio DX Ltd is rising to 1,210.20, reflecting a 4.93% increase after two days of decline. This rise is supported by strong sector performance and increased investor participation, although it remains below longer-term moving averages.

As of 13-Jul, the stock price of 3B Blackbio DX Ltd is rising, currently at 1,210.20, which reflects an increase of 56.9 points or 4.93%. This upward movement is notable as it comes after two consecutive days of decline, indicating a potential trend reversal. Additionally, the stock has outperformed its sector by 5.18% today, suggesting positive market sentiment towards it.<BR><BR>The stock reached an intraday high of Rs 1216, marking a 5.44% increase at its peak. Furthermore, there has been a significant rise in investor participation, with delivery volume increasing by 33.2% compared to the 5-day average, indicating growing interest among investors. While the stock is currently above its 5-day and 20-day moving averages, it remains below its longer-term moving averages (50-day, 100-day, and 200-day), which may suggest that while there is short-term momentum, there could be challenges in sustaining this upward trend in the longer term.<BR><BR>Overall, the combination of a rebound from previous declines, strong sector performance, and increased investor activity are contributing factors to the rise in the stock price of 3B Blackbio DX Ltd.

Which are the latest news on 3B Blackbio?

How big is 3B Blackbio?

As of 10th June, 3B Blackbio DX Ltd has a market capitalization of 1,043.00 Cr and reported net sales of 141.91 Cr and net profit of 58.59 Cr over the latest four quarters.

As of 10th June, 3:30 PM, <BR><BR>Market Cap: 3B Blackbio DX Ltd has a market capitalization of 1,043.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 141.91 Cr, while the sum of Net Profit for the same period is 58.59 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 268.42 Cr, and Total Assets amount to 295.72 Cr.

Who are in the management team of 3B Blackbio?

The management team of 3B Blackbio includes D K Dubey (Chairman & Managing Director), N K Dubey (Whole-time Director), Shabbar Husain, Abdul Moin Khan, and Harihar Prasad Thapak (Independent Directors), Mithala Dubey (Non-Executive Director), and Navneet Kaur (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

The management team of 3B Blackbio includes the following members:<BR><BR>1. **D K Dubey** - Chairman & Managing Director<BR>2. **N K Dubey** - Whole-time Director<BR>3. **Shabbar Husain** - Independent Director<BR>4. **Mithala Dubey** - Non-Executive Director<BR>5. **Navneet Kaur** - Company Secretary & Compliance Officer<BR>6. **Abdul Moin Khan** - Independent Director<BR>7. **Harihar Prasad Thapak** - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the 3B Blackbio?

3B Blackbio's peers include Suraksha Diagnostics, Laxmi Dental, Tarsons Products, One Global Services, Health X Platform, Hemant Surgical, and Prevest Denpro. In terms of management risk, growth, and capital structure, they vary, with One Global Services showing the highest 1-year return at 106.78% and 3B Blackbio at -23.84%.

Peers: The peers of 3B Blackbio are Suraksha Diagno., Laxmi Dental, Tarsons Products, One Global Serv, Health X Platfor, Hemant Surgical, and Prevest Denpro.<BR><BR>Quality Snapshot: Excellent management risk is observed at Suraksha Diagno. and Prevest Denpro, while Average management risk is found at Laxmi Dental, One Global Serv, Hemant Surgical, and 3B Blackbio, and Below Average management risk is noted at Tarsons Products and Health X Platfor. Good growth is seen at Suraksha Diagno., Laxmi Dental, Hemant Surgical, and One Global Serv, while Average growth is found at Health X Platfor, and Below Average growth is noted at Tarsons Products and 3B Blackbio. Excellent capital structure is present at Laxmi Dental, One Global Serv, 3B Blackbio, Health X Platfor, and Prevest Denpro, while Good capital structure is observed at Suraksha Diagno., Tarsons Products, and Hemant Surgical.<BR><BR>Return Snapshot: The peer with the highest 1-year return is One Global Serv at 106.78%, while the lowest is Laxmi Dental at -48.34%. 3B Blackbio's 1-year return is -23.84%, which is higher than Laxmi Dental but lower than One Global Serv. Additionally, the peers with negative six-month returns include Laxmi Dental, Tarsons Products, Health X Platfor, Prevest Denpro, and 3B Blackbio.

What does 3B Blackbio do?

3B Blackbio DX Ltd is a micro-cap healthcare services company that focuses on biotechnology, with recent quarterly net sales of 35 Cr and a net profit of 10 Cr as of March 2026. The company was formed from a merger in August 2023 and has a market cap of INR 1,043 Cr.

Overview: <BR>3B Blackbio DX Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated on May 25, 1972, originally as Kilpest India Limited. It underwent a merger with 3B BlackBio Biotech India Limited, leading to a name change to 3B Blackbio DX Limited in August 2023. The most recent quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 35 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 10 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,043 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 18.00 <BR>Industry P/E: 29 <BR>Dividend Yield: 0.33% <BR>Debt-Equity: -0.30 <BR>Return on Equity: 18.06% <BR>Price to Book: 3.20 <BR><BR>Contact Details: <BR>Address: 7-C Industrial Area, Govindpura Bhopal Madhya Pradesh : 462023 <BR>Tel: 91-0755-2586536/2586537 <BR>Email: kilpestbpl@yahoo.co.in/kilpest@bsnl <BR>Website: http://www.kilpest.com

Should I buy, sell or hold 3B Blackbio DX Ltd?

Are 3B Blackbio DX Ltd latest results good or bad?

The latest results for 3B Blackbio DX Ltd are concerning, showing a 57.47% year-on-year revenue growth but a significant quarter-on-quarter decline in net profit by 56.01% and sales by 29.63%, alongside a sharp drop in operating margin and heavy reliance on non-operating income. Overall, these factors suggest potential issues with the company's operational health and future growth prospects.

The latest results for 3B Blackbio DX Ltd present a mixed picture, leaning towards negative. While the company reported a year-on-year revenue growth of 57.47% in Q4 FY26, this was overshadowed by a significant quarter-on-quarter decline in both net profit and sales, with net profit dropping by 56.01% and net sales decreasing by 29.63%. <BR><BR>The operating margin also saw a sharp contraction, falling to 23.96% from 43.14% in the previous quarter, indicating serious cost control issues. Additionally, the company's reliance on other income, which constituted 69.28% of profit before tax, raises concerns about the sustainability of its earnings. <BR><BR>Overall, despite some positive year-on-year growth figures, the deterioration in profitability and margins, along with the heavy dependence on non-operating income, suggest that the results are more concerning than favorable. Investors may view these developments as red flags regarding the company's operational health and future growth prospects.

When is the next results date for 3B Blackbio DX Ltd?

The next results date for 3B Blackbio DX Ltd is 29 May 2026.

The next results date for 3B Blackbio DX Ltd is scheduled for 29 May 2026.

Is 3B Blackbio technically bullish or bearish?

As of November 17, 2025, 3B Blackbio's trend has shifted to a bearish stance with moderate strength, supported by daily moving averages and Bollinger Bands, despite mixed signals from the MACD across different time frames.

As of 17 November 2025, the technical trend for 3B Blackbio has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this conclusion include the daily moving averages indicating bearish momentum, and the weekly and monthly Bollinger Bands also signaling bearish conditions. The MACD shows a mildly bullish signal on the weekly chart but is mildly bearish on the monthly, indicating mixed signals across time frames. Overall, the bearish trend is reinforced by the Dow Theory, which is mildly bearish on both weekly and monthly assessments.

How has been the historical performance of 3B Blackbio?

3B Blackbio has shown significant improvement in financial performance, with net sales rising from 61.84 Cr in Mar'23 to 96.47 Cr in Mar'25, and profit after tax increasing from 25.94 Cr to 47.69 Cr during the same period, alongside reduced expenditures and enhanced cash flow. Overall, the company has demonstrated recovery and growth in its financial metrics.

Answer:<BR>The historical performance of 3B Blackbio shows a fluctuating trend in net sales and profitability over the years, with recent improvements noted.<BR><BR>Breakdown:<BR>3B Blackbio's net sales have increased from 61.84 Cr in Mar'23 to 96.47 Cr in Mar'25, following a dip in Mar'22. The total operating income also reflects this upward trend, reaching 96.47 Cr in Mar'25. The company has managed to reduce its total expenditure, which was 76.75 Cr in Mar'21, down to 46.36 Cr in Mar'25. Consequently, the operating profit (PBDIT) has significantly improved, rising from 29.15 Cr in Mar'23 to 50.11 Cr in Mar'25. Profit before tax has also shown a positive trajectory, increasing from 35.31 Cr in Mar'23 to 64.00 Cr in Mar'25, while profit after tax has grown from 25.94 Cr in Mar'23 to 47.69 Cr in Mar'25. The company's total assets have expanded from 214.06 Cr in Mar'23 to 295.72 Cr in Mar'25, indicating a solid growth in financial standing. Cash flow from operating activities has also improved, reaching 43.00 Cr in Mar'25, contributing to a net cash inflow of 6.00 Cr for the same period. Overall, 3B Blackbio has demonstrated a recovery and growth in its financial metrics over the recent years.

Who are the top shareholders of the 3B Blackbio?

The top shareholders of 3B Blackbio include Mithla Dubey with 12.35%, Rashi Daga with 5.3%, and individual investors holding 43.17%. There are no pledged promoter holdings or mutual funds involved.

The top shareholders of 3B Blackbio include Mithla Dubey, who holds the highest stake among promoters at 12.35%. The highest public shareholder is Rashi Daga, with a holding of 5.3%. Additionally, individual investors collectively own 43.17% of the company. There are also three foreign institutional investors (FIIs) that hold a combined 2.7%. Notably, there are no pledged promoter holdings and no mutual funds involved in the shareholding.

Is 3B Blackbio overvalued or undervalued?

As of August 11, 2022, 3B Blackbio is considered very expensive and overvalued, with a PE ratio of 29.13, an EV to EBITDA of 26.29, and a PEG ratio of 1.04, despite having a lower PE ratio than Bayer CropScience and P I Industries, but higher than UPL, while its stock has declined 19.90% year-to-date compared to the Sensex's 5.63% gain.

As of 11 August 2022, the valuation grade for 3B Blackbio has moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued. Key ratios include a PE ratio of 29.13, an EV to EBITDA of 26.29, and a PEG ratio of 1.04, which suggest that the stock is trading at a premium compared to its earnings growth potential.<BR><BR>In comparison to its peers, 3B Blackbio's PE ratio is lower than that of Bayer CropScience at 43.48 and P I Industries at 35.59, both of which are also classified as very expensive. However, it is notably higher than UPL, which is rated as attractive with a PE ratio of 38.74. Recent stock performance shows a decline of 19.90% year-to-date, contrasting sharply with the Sensex's gain of 5.63%, reinforcing the notion that the stock may be overvalued in the current market context.

Has 3B Blackbio declared dividend?

Yes, 3B Blackbio DX Ltd has declared a 30% dividend, amounting to 3 per share, with an ex-date of September 17, 2024. Recent total returns show volatility, with a -16.3% return over the last 6 months but strong performance over longer periods, including a 1282.3% return over the past 5 years.

3B Blackbio DX Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 0.18%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -16.3%, with a dividend return of 0%, resulting in a total return of -16.3%.<BR><BR>Over the past year, the price return was 78.18%, the dividend return was 0.26%, leading to a total return of 78.44%.<BR><BR>In the 2-year period, the price return was 286.4%, the dividend return was 1.30%, culminating in a total return of 287.7%.<BR><BR>For the 3-year period, the price return was 368.71%, with a dividend return of 2.40%, resulting in a total return of 371.11%.<BR><BR>In the last 4 years, the price return was 278.08%, the dividend return was 2.66%, leading to a total return of 280.74%.<BR><BR>Finally, over the past 5 years, the price return was 1273.79%, with a dividend return of 8.51%, resulting in a total return of 1282.3%.<BR><BR>Overall, while 3B Blackbio DX Ltd has declared a dividend, the recent total returns indicate significant volatility, particularly in the short term, contrasting with strong performance over longer periods.